How effective is the average therapeutic dose of a nonsteroidal anti-inflammatory drug in osteoarthritis?
The international multicenter PRECISION study evaluating the cardiovascular safety of celecoxib, naproxen, and ibuprofen is under close scrutiny by critics. One of the criticisms about this study was that the use of relatively low dose (on average just above 200 mg/day) may not be effective enough....
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2019-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/895 |
| _version_ | 1826556932875354112 |
|---|---|
| author | A. E. Karateev |
| author_facet | A. E. Karateev |
| author_sort | A. E. Karateev |
| collection | DOAJ |
| description | The international multicenter PRECISION study evaluating the cardiovascular safety of celecoxib, naproxen, and ibuprofen is under close scrutiny by critics. One of the criticisms about this study was that the use of relatively low dose (on average just above 200 mg/day) may not be effective enough. But is it really so?This review gives data from numerous international studies dealing with the treatment of osteoarthritis (OA), in which celecoxib 200 mg/day is compared with paracetamol 4000 mg/day, diclofenac 100—150 mg/day, naproxen 1000 mg/day, ibuprofen 2400 mg/day and slow-acting antirheumatic drugs (glucosamine, chondroitin, and their combination). Almost all studies demonstrate that celecoxib 200 mg has a good and rapid analgesic effect that is not inferior to or exceed that of the reference drugs.Celecoxib 200 mg/day could relieve pain in OA for many months and prevent disease recurrences. The low risk of gastrointestinal and cardiovascular complications, which has been confirmed by the PRECISION study, makes celecoxib 200 mg/day the drug of choice for long-term OA therapy, including in patients with serious comorbid conditions. |
| first_indexed | 2024-04-10T02:06:50Z |
| format | Article |
| id | doaj.art-df89f88db1a749999ec5fe58ffbfc477 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2025-03-14T08:20:34Z |
| publishDate | 2019-03-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-df89f88db1a749999ec5fe58ffbfc4772025-03-02T13:11:01ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2019-03-0113110811310.14412/1996-7012-2019-1-108-1132156How effective is the average therapeutic dose of a nonsteroidal anti-inflammatory drug in osteoarthritis?A. E. Karateev0V.A. Nasonova Research Institute of RheumatologyThe international multicenter PRECISION study evaluating the cardiovascular safety of celecoxib, naproxen, and ibuprofen is under close scrutiny by critics. One of the criticisms about this study was that the use of relatively low dose (on average just above 200 mg/day) may not be effective enough. But is it really so?This review gives data from numerous international studies dealing with the treatment of osteoarthritis (OA), in which celecoxib 200 mg/day is compared with paracetamol 4000 mg/day, diclofenac 100—150 mg/day, naproxen 1000 mg/day, ibuprofen 2400 mg/day and slow-acting antirheumatic drugs (glucosamine, chondroitin, and their combination). Almost all studies demonstrate that celecoxib 200 mg has a good and rapid analgesic effect that is not inferior to or exceed that of the reference drugs.Celecoxib 200 mg/day could relieve pain in OA for many months and prevent disease recurrences. The low risk of gastrointestinal and cardiovascular complications, which has been confirmed by the PRECISION study, makes celecoxib 200 mg/day the drug of choice for long-term OA therapy, including in patients with serious comorbid conditions.https://mrj.ima-press.net/mrj/article/view/895nonsteroidal anti-inflammatory drugscelecoxibefficacycomplicationscardiovascular riskgastrointestinal tractosteoarthritis |
| spellingShingle | A. E. Karateev How effective is the average therapeutic dose of a nonsteroidal anti-inflammatory drug in osteoarthritis? Современная ревматология nonsteroidal anti-inflammatory drugs celecoxib efficacy complications cardiovascular risk gastrointestinal tract osteoarthritis |
| title | How effective is the average therapeutic dose of a nonsteroidal anti-inflammatory drug in osteoarthritis? |
| title_full | How effective is the average therapeutic dose of a nonsteroidal anti-inflammatory drug in osteoarthritis? |
| title_fullStr | How effective is the average therapeutic dose of a nonsteroidal anti-inflammatory drug in osteoarthritis? |
| title_full_unstemmed | How effective is the average therapeutic dose of a nonsteroidal anti-inflammatory drug in osteoarthritis? |
| title_short | How effective is the average therapeutic dose of a nonsteroidal anti-inflammatory drug in osteoarthritis? |
| title_sort | how effective is the average therapeutic dose of a nonsteroidal anti inflammatory drug in osteoarthritis |
| topic | nonsteroidal anti-inflammatory drugs celecoxib efficacy complications cardiovascular risk gastrointestinal tract osteoarthritis |
| url | https://mrj.ima-press.net/mrj/article/view/895 |
| work_keys_str_mv | AT aekarateev howeffectiveistheaveragetherapeuticdoseofanonsteroidalantiinflammatorydruginosteoarthritis |